CoChat

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma

Leung, Grace P., Feng, Tianshu, Sigoillot, Frederic D., Geyer, Felipe C., Shirley, Matthew D., Ruddy, David A., Rakiec, Daniel P., Freeman, Alyson K., Engelman, Jeffrey A., Jaskelioff, Mariela, Stuart, Darrin D. · 2019 · Molecular Cancer Research
Cited by 73

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The most frequent genetic alterations in melanoma are gain-of-function (GOF) mutations in BRAF, which result in RAF–MEK–ERK signaling pathway addiction. Despite therapeutic success of RAF and MEK inhibitors in treating BRAFV600-mutant tumors, a major challenge is the inevitable emergence of drug resistance, which often involves reactivation of the MAPK pathway. Interestingly, resistant tumors are often sensitive to drug withdrawal, suggesting that hyperactivation of the MAPK pathway is not tolerated. To further characterize this phenomenon, isogenic models of inducible MAPK hyperactivation in BRAFV600E melanoma cells were generated by overexpression of ERK2. Using this model system, supraphysiologic levels of MAPK signaling led to cell death, which was reversed by MAPK inhibition. Furthermore, complete tumor regression was observed in an ERK2-overexpressing xenograft model. To identify mediators of MAPK hyperactivation–induced cell death, a large-scale pooled shRNA screen was conducted, which revealed that only shRNAs against BRAF and MAP2K1 rescued loss of cell viability. This suggested that no single downstream ERK2 effector was required, consistent with pleiotropic effects on multiple cellular stress pathways. Intriguingly, the detrimental effect of MAPK hyperactivation could be partially attributed to secreted factors, and more than 100 differentially secreted proteins were identified. The effect of ERK2 overexpression was highly context dependent, as RAS/RAF mutant but not RAS/RAF wild-type melanoma were sensitive to this perturbation. Implications: This vulnerability to MAPK hyperactivation raises the possibility of novel therapeutic approaches for RAS/RAF-mutant cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-18-0327

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 73

Metadata

Authors
Leung, G. P., Feng, T., Sigoillot, F. D., Geyer, F. C., Shirley, M. D., Ruddy, D. A., Rakiec, D. P., Freeman, A. K., Engelman, J. A., Jaskelioff, M., & Stuart, D. D.
Venue
Molecular Cancer Research
Published
2019-01-01
Volume
17
Issue
1
Pages
199-211
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2891996609
Cited by
73
References
16
FWCI
1.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-18-0327
The paper
Leung, G. P., Feng, T., Sigoillot, F. D., Geyer, F. C., Shirley, M. D., Ruddy, D. A., Rakiec, D. P., Freeman, A. K., Engelman, J. A., Jaskelioff, M., & Stuart, D. D. (2019). Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-18-0327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.